Alvason Z. Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alvason Z. Li has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Amalia S. Magaret
University of Washington, Seattle, WA, United States
1 shared publication - Aude G. Chapuis
Translational Sciences and Therapeutics Division, Fred Hutch Cancer Center, Seattle, Washington, USA
1 shared publication - Christine Johnston
University of Washington
1 shared publication - David M. Koelle
Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA
1 shared publication - Emily S. Ford
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington
1 shared publication - Jack L. Reid
Translational Sciences and Therapeutics Division, Fred Hutch Cancer Center, Seattle, Washington, USA
1 shared publication
Latest Publications
- Open Access
- 18 June 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (14)
Expansion of the HSV-2–specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccine
The skin at the site of HSV-2 reactivation is enriched for HSV-2–specific T cells. To evaluate whether an immunotherapeutic vaccine could elicit skin-based memory T cells, we studied skin biopsies and HSV-2–reactive CD4 + T cells from PBMCs by T cell receptor (TCR) β chain ( TRB ) sequencing before and after vaccination with a replication-incompetent whole-virus HSV-2 vaccine candidate (HSV529). The representation of HSV-2–reactive CD4 + TRB sequences from PBMCs in the skin TRB repertoire increased after the first vaccine dose. We found sustained expansion after vaccination of unique, skin-based T cell clonotypes that were not detected in HSV-2–reactive CD4 + T cells isolated from PBMCs. In one participant, a switch in immunodominance occurred with the emergence of a TCR αβ pair after vaccination that was not detected in blood. This TCRαβ was shown to be HSV-2 reactive by expression of a synthetic TCR in a Jurkat-based NR4A1 reporter system. The skin in areas of HSV-2 reactivation possessed an oligoclonal TRB repertoire that was distinct from the circulation. Defining the influence of therapeutic vaccination on the HSV-2–specific TRB repertoire requires tissue-based evaluation.
- 18 June 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (14)
Open AccessExpansion of the HSV-2–specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccine
The skin at the site of HSV-2 reactivation is enriched for HSV-2–specific T cells. To evaluate whether an immunotherapeutic vaccine could elicit skin-based memory T cells, we studied skin biopsies and HSV-2–reactive CD4 + T cells from PBMCs by T cell receptor (TCR) β chain ( TRB ) sequencing before and after vaccination with a replication-incompetent whole-virus HSV-2 vaccine candidate (HSV529). The representation of HSV-2–reactive CD4 + TRB sequences from PBMCs in the skin TRB repertoire increased after the first vaccine dose. We found sustained expansion after vaccination of unique, skin-based T cell clonotypes that were not detected in HSV-2–reactive CD4 + T cells isolated from PBMCs. In one participant, a switch in immunodominance occurred with the emergence of a TCR αβ pair after vaccination that was not detected in blood. This TCRαβ was shown to be HSV-2 reactive by expression of a synthetic TCR in a Jurkat-based NR4A1 reporter system. The skin in areas of HSV-2 reactivation possessed an oligoclonal TRB repertoire that was distinct from the circulation. Defining the influence of therapeutic vaccination on the HSV-2–specific TRB repertoire requires tissue-based evaluation.